Evidence map›Paper›PMID 33257571›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association.

Mo Zhou, Leena Kuruvilla, Xiarong Shi, Stephen Viviano, Ian M Ahearn, Caroline R Amendola, Wenjuan Su, Sana Badri, James Mahaffey, Nicole Fehrenbacher and 5 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Post-translational modification of RAS proteins.Current opinion in structural biology · 2021
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Mo ZhouPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
Leena KuruvillaDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.ORCID 0000-0001-8686-6654
Xiarong ShiDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.
Stephen VivianoDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.
Ian M AhearnPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
Caroline R AmendolaPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
Wenjuan SuPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.ORCID 0000-0002-2398-5100
Sana BadriPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
James MahaffeyPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
Nicole FehrenbacherPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.
Jane SkokPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016.ORCID 0000-0002-4145-1516
Joseph SchlessingerDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.ORCID 0000-0002-5085-5969
Benjamin E TurkDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.ORCID 0000-0001-9275-4069
David A CalderwoodDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06510.ORCID 0000-0002-0791-4142
Mark R PhilipsPerlmutter Cancer Center, NYU Langone Health, New York, NY 10016; philim01@nyulangone.org.ORCID 0000-0002-1179-8156
NYU Langone Health · USYale University · US

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1M
Nuclear organization and its role in gene regulationR35GM122515 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2017 to 2026
$7.1M
Differential function and tumor vulnerabilities revealed by RAS membrane traffickingR35CA253178 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 2020 to 2026
$6.8M
Regulation of K-Ras by a Farnesyl-electrostatic SwitchR01CA116034 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 2005 to 2017
$3.4M
Isoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1R01CA163489 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 2012 to 2020
$2.8M
Cutaneous Biology and Skin Disease Training ProgramT32AR064184 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ORLOW, SETH J. · 2014 to 2024
$2.1M
NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA116034NCI NIH HHS R01 CA163489NCI NIH HHS R35 CA253178NIAMS NIH HHS T32 AR064184NIGMS NIH HHS R35 GM122515
6 · The paper itself

Abstract

Inhibiting membrane association of RAS has long been considered a rational approach to anticancer therapy, which led to the development of farnesyltransferase inhibitors (FTIs). However, FTIs proved ineffective against

Indexed as

Alkyl and Aryl TransferasesCell MembraneComputational BiologyCRISPR-Cas SystemsDatasets as TopicDimethylallyltranstransferaseGene Knockdown TechniquesHumansMatrix Attachment Region Binding ProteinsNeoplasmsNuclear Matrix-Associated ProteinsProtein PrenylationProtein SubunitsProto-Oncogene Proteins p21(ras)Receptors, EstrogenAlkyl and Aryl TransferasesDimethylallyltranstransferaseFNTA protein, humanKRAS protein, humanMatrix Attachment Region Binding ProteinsNuclear Matrix-Associated ProteinsProtein SubunitsProto-Oncogene Proteins p21(ras)Receptors, EstrogenSAFB protein, humanfarnesyltransferaseKRASprenyltransferaseRASSAFB

Identifiers

PMID33257571
PMCPMC7749360
OpenAlexW3107455675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.